Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health Care Personnel, Long-Term Care Residents Should Get COVID-19 Vaccine First, ACIP Votes

Executive Summary

CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.

You may also be interested in...



Placebo-Unblinding Should Be Uniform Across COVID Vaccine Trials, Advisory Committee Says

US FDA’s outside advisors say Moderna should offer vaccine to placebo-arm patients when they are eligible, the same plan adopted for the Pfizer/BioNTech COVID-19 vaccine.

CDC ‘Threading A Needle’ On COVID Vaccine Contraindication Guidance After ACIP Vote

Allergic contraindication, use in pregnancy to be addressed in CDC guidance. Advisory committee urges language be modified to clarify that those with severe food and environmental allergies may receive the vaccine. At press briefing after FDA grants emergency use authorization to Pfizer/BioNTech’s COVID vaccine for persons in the US 16 years of age and older, CBER's Peter Marks addresses the 'foolhardy' conjecture that one dose is adequate.

Pfizer/BioNTech COVID-19 Vaccine's Positive Advisory Committee Complicated By Pediatric Issues

US FDA expected to quickly clear the first emergency use authorization for a COVID-19 vaccine following 17-4 VRBPAC vote, but a disorganized committee ending made it unclear why some members voted no. Pediatric data was at issue for at least two voters, though.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel